| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f47c750954e13a1ed0be96c1bf1c51c7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-46 |
| filingDate |
2013-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54f4a588f5dc72ab13b273bf4e3ee504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66d817a5310e06f2ebfde861d1651bbb |
| publicationDate |
2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-RE45020-E |
| titleOfInvention |
Ribonucleotide reductase inhibitors and methods of use |
| abstract |
Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015087844-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9126960-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9598385-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10155732-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9796692-B2 |
| priorityDate |
2008-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |